Lipid Nanoparticles As Carriers for RNAi Against Viral Infections: Current Status and Future Perspectives

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 Sep 4

PMID 25184135

Citations 20

Authors

Josune Torrecilla

Alicia Rodriguez-Gascon

Maria Angeles Solinis

Ana Del Pozo-Rodriguez

Affiliations

Soon will be listed here.

Abstract

The efforts made to develop RNAi-based therapies have led to productive research in the field of infections in humans, such as hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), human cytomegalovirus (HCMV), herpetic keratitis, human papillomavirus, or influenza virus. Naked RNAi molecules are rapidly digested by nucleases in the serum, and due to their negative surface charge, entry into the cell cytoplasm is also hampered, which makes necessary the use of delivery systems to exploit the full potential of RNAi therapeutics. Lipid nanoparticles (LNP) represent one of the most widely used delivery systems for in vivo application of RNAi due to their relative safety and simplicity of production, joint with the enhanced payload and protection of encapsulated RNAs. Moreover, LNP may be functionalized to reach target cells, and they may be used to combine RNAi molecules with conventional drug substances to reduce resistance or improve efficiency. This review features the current application of LNP in RNAi mediated therapy against viral infections and aims to explore possible future lines of action in this field.

Citing Articles

Singh M, Negi R, Alka , Vinayagam R, Kang S, Shukla P Medicina (Kaunas). 2024; 60(10).

PMID: 39459435 PMC: 11509623. DOI: 10.3390/medicina60101647.

Small interfering RNAs based therapies for intracerebral hemorrhage: challenges and progress in drug delivery systems.

Almarghalani D, Boddu S, Ali M, Kondaka A, Ta D, Shah R Neural Regen Res. 2022; 17(8):1717-1725.

PMID: 35017419 PMC: 8820693. DOI: 10.4103/1673-5374.332129.

New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery.

Niculescu A, Birca A, Grumezescu A Pharmaceutics. 2021; 13(12).

PMID: 34959335 PMC: 8708541. DOI: 10.3390/pharmaceutics13122053.

Nano-therapeutic strategies to target coronavirus.

Rauf M, Tasleem M, Bhise K, Tatiparti K, Sau S, Iyer A View (Beijing). 2021; 2(3):20200155.

PMID: 34766165 PMC: 8250313. DOI: 10.1002/VIW.20200155.

Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study.

Saify Nabiabad H, Amini M, Demirdas S Chem Biol Drug Des. 2021; 99(2):233-246.

PMID: 34714580 PMC: 8653378. DOI: 10.1111/cbdd.13978.

References

Beloqui A, Solinis M, des Rieux A, Preat V, Rodriguez-Gascon A . Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. Int J Pharm. 2014; 468(1-2):105-11. DOI: 10.1016/j.ijpharm.2014.04.027. View

Cui Z, Patel J, Tuzova M, Ray P, Phillips R, Woodward J . Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. Vaccine. 2004; 22(20):2631-40. DOI: 10.1016/j.vaccine.2003.12.013. View

Patel J, Galey D, Jones J, Ray P, Woodward J, Nath A . HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and neutralizing antibodies compared to alum adjuvant. Vaccine. 2006; 24(17):3564-73. DOI: 10.1016/j.vaccine.2006.01.065. View

Lu X, Yu Q, Binder G, Chen Z, Slepushkina T, Rossi J . Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J Virol. 2004; 78(13):7079-88. PMC: 421644. DOI: 10.1128/JVI.78.13.7079-7088.2004. View

Elbashir S, Lendeckel W, Tuschl T . RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001; 15(2):188-200. PMC: 312613. DOI: 10.1101/gad.862301. View

Perez Ruiz de Garibay A, Delgado D, Del Pozo-Rodriguez A, Solinis M, Gascon A . Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy. Drug Des Devel Ther. 2012; 6:303-10. PMC: 3484727. DOI: 10.2147/DDDT.S36131. View

Triboulet R, Mari B, Lin Y, Chable-Bessia C, Bennasser Y, Lebrigand K . Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science. 2007; 315(5818):1579-82. DOI: 10.1126/science.1136319. View

Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E . Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther. 2003; 8(5):769-76. DOI: 10.1016/s1525-0016(03)00244-2. View

Arima H, Yoshimatsu A, Ikeda H, Ohyama A, Motoyama K, Higashi T . Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-selective siRNA delivery carrier. Mol Pharm. 2012; 9(9):2591-604. DOI: 10.1021/mp300188f. View

10.

Del Pozo-Rodriguez A, Delgado D, Gascon A, Solinis M . Lipid nanoparticles as drug/gene delivery systems to the retina. J Ocul Pharmacol Ther. 2013; 29(2):173-88. DOI: 10.1089/jop.2012.0128. View

11.

Weinberg M, Arbuthnot P . Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection. Genome Med. 2010; 2(4):28. PMC: 2873806. DOI: 10.1186/gm149. View

12.

Geall A, Verma A, Otten G, Shaw C, Hekele A, Banerjee K . Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012; 109(36):14604-9. PMC: 3437863. DOI: 10.1073/pnas.1209367109. View

13.

Kwon S, Nam H, Nam T, Park K, Lee S, Kim K . In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier. J Control Release. 2008; 128(1):89-97. DOI: 10.1016/j.jconrel.2008.02.004. View

14.

Jiang W . Blockade of B7-H1 enhances dendritic cell-mediated T cell response and antiviral immunity in HBV transgenic mice. Vaccine. 2011; 30(4):758-66. DOI: 10.1016/j.vaccine.2011.11.076. View

15.

Aditya N, Patankar S, Madhusudhan B, Murthy R, Souto E . Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: Pharmacokinetics, toxicological and in vivo anti-malarial activity. Eur J Pharm Sci. 2010; 40(5):448-55. DOI: 10.1016/j.ejps.2010.05.007. View

16.

Arias M, Loxley A, Eatmon C, Roey G, Fairhurst D, Mitchnick M . Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. Vaccine. 2010; 29(6):1258-69. PMC: 3098439. DOI: 10.1016/j.vaccine.2010.11.084. View

17.

Khantasup K, Kopermsub P, Chaichoun K, Dharakul T . Targeted small interfering RNA-immunoliposomes as a promising therapeutic agent against highly pathogenic Avian Influenza A (H5N1) virus infection. Antimicrob Agents Chemother. 2014; 58(5):2816-24. PMC: 3993214. DOI: 10.1128/AAC.02768-13. View

18.

Del Pozo-Rodriguez A, Solinis M, Gascon A, Pedraz J . Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur J Pharm Biopharm. 2008; 71(2):181-9. DOI: 10.1016/j.ejpb.2008.09.015. View

19.

Chen X, Zhu K, Xu Y, Tang X, Cai X, Zhang X . RNA interference silences the human papillomavirus 6b/11 early gene E7 in vitro and in vivo. Clin Exp Dermatol. 2009; 35(5):509-15. DOI: 10.1111/j.1365-2230.2009.03624.x. View

20.

Sheridan C . Gene therapy finds its niche. Nat Biotechnol. 2011; 29(2):121-8. DOI: 10.1038/nbt.1769. View